(USD) | Sep 2023 | Q/Q |
---|---|---|
Revenue | 346K | -65% |
Operating Income | -59MM | +11% |
Operating Expenses | 59.3MM | +10% |
Net Income | -57.5MM | +13% |
R&D | 43.8MM | +8% |
G&A | 15.5MM | +16% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Jeff Knight, the Chief Operating Officer of Crinetics Pharmaceuticals Inc (NASDAQ:CRNX), has sold 32,359 shares of the company on March 22, 2024, according to a recent SEC filing.
Chief Medical and Development Officer Dana Pizzuti of Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) sold 15,089 shares of the company on March 20, 2024, according to a recent SEC filing.
Director Matthew Fust has sold 60,000 shares of Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) on March 20, 2024, according to a recent SEC Filing.
Geron Corporation (GERN) and Crinetics Pharmaceuticals (CRNX) gain on positive regulatory and study updates.
Marc Wilson, Chief Financial Officer of Crinetics Pharmaceuticals Inc (NASDAQ:CRNX), has sold 6,942 shares of the company on March 19, 2024, according to a recent SEC Filing.
Crinetics Pharmaceuticals (CRNX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Tuesday, Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) released topline results from PATHFNDR-2, the second of two Phase 3 studies evaluating the efficacy and safety of paltusotine for acromegaly. Acromegaly is a hormonal disorder that develops when the pituitary gland produces too much growth hormone during adulthood. The 111-participant study met statistical significance (p<0.0001) on the primary endpoint, based on the proportion of participants taking paltusotine (56%) who achieved an insulin-l
Crinetics Pharmaceuticals said Tuesday its acromegaly treatment succeeded in a second Phase 3 study. The biotech stock bolted higher.
Crinetics Pharmaceuticals said on Tuesday its experimental drug to treat a rare hormonal disorder met the main goal of the second of two late-stage studies, putting the company on track to seek U.S. approval later this year. Shares of the San Diego, California-based drug developer jumped 8.2% in premarket trading. The daily oral drug, called paltusotine, is being tested in patients with acromegaly, a rare disease caused by benign tumors that lead to high levels of the growth hormone.
56% of Participants on Paltusotine Achieved IGF-1 ≤1.0 xULN vs. 5% on Placebo (p<0.0001) Paltusotine was Generally Well-tolerated with No Serious Adverse Events Positive Topline Results Support Planned NDA Submission to the FDA in 2H 2024 Management Will Host a Conference Call Today at 8:30 a.m. Eastern Time SAN DIEGO, March 19, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) a clinical stage pharmaceutical company focused on the discovery, development and commercializati